Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.61 |
| ▸ | NPC1 | O15118 | 3/20 | 0.61 |
| ▸ | RAB9A | P51151 | 3/20 | 0.61 |
| ▸ | PKM | P14618 | 2/20 | 0.61 |
| ▸ | AMY1A | P0DUB6 | 5/20 | 0.58 |
| ▸ | MAPT | P10636 | 6/20 | 0.57 |
| ▸ | GAA | P10253 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | USP2 | O75604 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | PARP1 | P09874 | 1/20 | 0.56 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7395130 | 0.87 | AMY1A (0.69) | ALDH1A1SMN1; SMN2KDM4ENPC1RAB9A | |
| SCHEMBL22301855 | 0.85 | CDK4 (0.56) | ALDH1A1SMN1; SMN2KDM4ENPC1RAB9A | |
| SCHEMBL12470605 | 0.85 | ALOX5 (0.70) | ALDH1A1SMN1; SMN2KDM4ENPC1RAB9A | |
| SCHEMBL2089968 | 0.85 | ALDH1A1 (0.61) | ALDH1A1SMN1; SMN2KDM4ENPC1RAB9A | |
| SCHEMBL18292411 | 0.84 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2KDM4ENPC1RAB9A | |
| SCHEMBL24140790 | 0.84 | AMY1A (0.62) | ALDH1A1SMN1; SMN2KDM4ENPC1RAB9A | |
| SCHEMBL17255224 | 0.83 | FOXO1 (0.53) | ALDH1A1SMN1; SMN2KDM4ENPC1RAB9A | |
| SCHEMBL17393308 | 0.83 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2KDM4ENPC1RAB9A | |
| SCHEMBL7916899 | 0.82 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2KDM4ENPC1RAB9A | |
| SCHEMBL16148274 | 0.82 | HDAC1 (0.55) | ALDH1A1SMN1; SMN2KDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122017251-A | Marker group for sarcopenia screening and diagnosis and application thereof | 四川大学华西医院 | 2026-05-12 | — | — | CN | claimed |
| WO-2012108689-A2 | NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREFOR | 부산대학교 산학협력단 (KR) | 2012-08-16 | — | — | WO | claimed |
| CN-122017251-A | Marker group for sarcopenia screening and diagnosis and application thereof | 四川大学华西医院 | 2026-05-12 | — | — | CN | disclosed |
| CN-104072425-B | Benzimidazole compound and application thereof | 大连理工大学 | 2016-12-07 | — | — | CN | disclosed |
| US-20150366776-A1 | NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREOF | PUSAN NAT UNIV IND COOP FOUND (KR) | 2015-12-24 | — | — | US | disclosed |
| US-9155690-B2 | Compound having skin-whitening, anti-oxidizing and PPAR activities and medical use thereof | PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION (KR) | 2015-10-13 | — | — | US | disclosed |
| US-8889881-B2 | Compound having skin-whitening, anti-oxidizing and PPAR activities and medical use therefor | Pusan National University Industry —University Cooperation Foundation (KR) | 2014-11-18 | — | — | US | disclosed |
| US-20140037564-A1 | NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREFOR | Pusan National University Indusrtyuniversity (KR) | 2014-02-06 | — | — | US | disclosed |
| WO-2012108689-A2 | NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREFOR | 부산대학교 산학협력단 (KR) | 2012-08-16 | — | — | WO | disclosed |
| US-6211177-B1 | SIDE EFFECT REDUCTION | CELL PATHWAYS, INC. | 2001-04-03 | — | — | US | disclosed |
| US-6030992-A | ANTAGONISTS FOR THE BINDING OF NEUROKININ-2 RECEPTOR; SLEEP DISORDERS; BENZIMIDES, 2- OR 3-ALKOXYBENZIMIDES AND 2,3-DIALKOXYBENZIMIDES | ELI LILLY AND COMPANY (US) | 2000-02-29 | — | — | US | disclosed |
| US-6025379-A | A SUBSTITUTED BENZIMIDAZOLE, TACHYKININ RECEPTOR ANTAGONISTS, | ELI LILLY AND COMPANY (US) | 2000-02-15 | — | — | US | disclosed |
| WO-1997033873-A1 | METHODS OF TREATING OR PREVENTING INTERSTITIAL CYSTITIS | ELI LILLY AND COMPANY (US) | 1997-09-18 | — | — | WO | disclosed |
| WO-1997031635-A1 | METHODS OF TREATING OR PREVENTING SLEEP APNEA | ELI LILLY AND COMPANY (US) | 1997-09-04 | — | — | WO | disclosed |
| US-5552426-A | NERVOUS SYSTEM DISORDERS USING IMIDAZOLE DERIVITIVES | ELI LILLY AND COMPANY (US) | 1996-09-03 | — | — | US | disclosed |
| EP-0694535-A1 | Non-peptidyl tachykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 1996-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150366776-A1 | NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREOF | PPARG, PPARA, TYR | ALDH1A1 213/4885SMN1; SMN2 3671/4885KDM4E 3430/4885 |
| US-20140037564-A1 | NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREFOR | PPARG, PPARA, PPARD | ALDH1A1 186/4885SMN1; SMN2 4087/4885KDM4E 3588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.